Cardiovascular Risk Assessment: A Systematic Review of Guidelines.
|
|
- Tyler Dennis Walker
- 5 years ago
- Views:
Transcription
1 Cardiovascular Risk Assessment: A Systematic Review of Guidelines. Khanji, MY; Bicalho, VVS; van Waardhuizen, CN; Ferket, BS; Petersen, SE; Hunink, MGM 2016 American College of Physicians This is a pre-copyedited, author-produced PDF of an article accepted for publication in Annals of Internal Medicine following peer review. The version of record is available For additional information about this publication click this link. Information about this research object was correct at the time of download; we occasionally make corrections to records, please therefore check the published record when citing. For more information contact scholarlycommunications@qmul.ac.uk
2 1 TitlePage CardiovascularRiskAssessment: ASystematicReviewofGuidelines MohammedY.Khanji *, MBBCh,ViníciusV.S.Bicalho MD,ClaudiaN.vanWaardhuizen MSc, BartS.Ferket PhD,SteffenE.Petersen * DPHIL,M.G.MyriamHunink, PhD Authors MohammedY.Khanji,MBBCh; E:m.khanji@qmul.ac.uk ViníciusV.S.Bicalho,MD; E:vsbicalho@gmail.com ClaudiaN.vanWaardhuizen,MSc; E:c.vanwaardhuizen@erasmusmc.nl BartS.Ferket,PhD; E:bart.ferket@mountsinai.org SteffenE.Petersen,DPHIL; E:s.e.petersen@qmul.ac.uk M.G.MyriamHunink,PhD (correspondingauthor) E:m.hunink@erasmusmc.nl *CentreforAdvancedCardiovascularImaging,NIHRCardiovascularBiomedicalResearchUnitat Barts,WilliamHarveyResearchInstitute,QueenMaryUniversityofLondon,London,United Kingdom. DepartmentofCardiology,MorristonHospital,Swansea,UnitedKingdom SchoolofMedicine,UniversidadeFederaldeJuizdeFora,Brazil. DepartmentofClinicalEpidemiologyandRadiology,ErasmusMC,Rotterdam,TheNetherlands. InstituteforHealthcareDeliveryScience,DepartmentofPopulationHealthScienceandPolicy, IcahnSchoolofMedicineatMountSinai,NewYork,NY,USA. CenterforHealthDecisionSciences,HarvardT.H.ChanSchoolofPublicHealth,Boston,MA,USA.
3 Abstractwordcount:274words 25 Manuscripttextwordcount:3716words Correspondingauthor: 28 M.G.MyriamHunink,MD,PhD 29 RoomNa ErasmusMC 31 POBox2040,3000CA,Rotterdam,TheNetherlands 32 Tel: /Fax:
4 Abstract 50 Background: 51 Anumberofguidelinesexistforprimarypreventioncardiovascularscreeningandriskassessment 52 fortheapparentlyhealthypopulation. 53 Purpose: 54 Tosystematicallyreviewcurrentprimarypreventionguidelinesonadultcardiovascularrisk 55 assessmentandhighlightthesimilaritiesanddifferencesinordertoaidclinician sdecisionn 56 making. 57 Datasources: 58 PublicationsinMEDLINEandCINAHLbetweenMay3,2009andJune30,2016wereidentified.In 59 additiononjune30,2016wesearchedthegninninternationalguidelinelibrary,national 60 GuidelinesClearingnhouse,NationalLibraryforHealth,CanadianMedicalAssociationInfoBaseand 61 websitesoforganizationsresponsibleforguidelinesdevelopment. 62 Studyselection: 63 TworeviewersscreenedtitlesandabstractstoidentifyguidelinesfromWesterncountries 64 containingrecommendationsforcardiovascularriskassessmentforhealthyadults. 65 Dataextraction: 66 TworeviewersindependentlyassessedrigorofguidelinedevelopmentusingAGREEIIandone 67 extractedtherecommendations. 68 Datasynthesis: 69 Ofthe21guidelines,17showedconsiderablerigorofguidelinedevelopment.Therigorously 70 developedrecommendationsaddressassessmentoftotalcardiovascularrisk(5guidelines), 71 dysglycemia(7),dyslipidemia(2),andhypertension(3).allrecommendations,withtheexception 72 ofone,advocatescreeningandthemajorityincludepredictionmodelsintegratingmultiple, 73 relativelysimpleriskfactorseitherfordecidingonfurtherscreeningortoguidesubsequent 74
5 management.thereisnoconsensusonthestrategyforscreening,recommendedtarget 75 population,screeningtestsortreatmentthresholds. 76 Limitations: 77 OnlyguidelinesdevelopedbyWesternnationalorinternationalmedicalorganizationsare 78 included. 79 Conclusion: 80 Considerablediscrepanciesinrecommendationsstillexistincardiovascularscreeningguidelines 81 withnoconsensusonoptimumscreeningstrategiesortreatmentthreshold Primaryfundingsource: 84 AspartofaBartsCharitylargeprojectgrant.Thecharityhadnoinputinthepreparationorediting 85 ofthemanuscript
6 Introduction Manynationalandinternationalbodieshighlightprimarypreventionofcardiovasculardisease (CVD),throughriskfactorreduction,asapotentialsolutiontoreducefutureburden(1).The optimaltargetgroupandinterventionthatmaximizebenefit,however,remainunclear. CardiovascularscreeningthroughhealthchecksarenowwidelyimplementedinmanyWestern countriestosystematicallydetecthighnriskindividualswhomayrequireaggressiveriskreduction throughpharmacotherapyand/orlifestyleinterventions.guidelinesadvocateuseofscreening withtheaimofmakingtheapparentlyhealthypopulationhealthierandreducingriskfactorsfor futurecvd.theinstituteofmedicine(iom)definesclinicalpracticeguidelinesas systematically developedstatementstoassistpractitionersandpatientdecisionsabouttheappropriatehealth careforspecificclinicalcircumstances (2).However,todateaninternationallyagreedguideline forcardiovascularhealthchecksdoesnotexist. PrimarycarephysiciansmaintainacentralroleinthepreventionofCVDbutstillfind implementationofpreventionstrategieschallengingandmanagementofthosewithincreased CVDriskremainssuboptimal(3).Timeconstraints,lackofperceivedusefulness,inadequate knowledge,andinconsistencyinpublishedrecommendationshavebeencitedascommonreasons fornotusingcvdpreventionguidelinesorglobalcvdriskassessmenttools(4).concernsexist regardingpooruptakeoftheprogrambythoseinvitedwithonlyabout50%attendingfora NationalHealthServicehealthcheck,muchlowerthanthe75%governmenttarget(5). Additionally,therearedoubtsraisedconcerningthemorbidityandmortalitybenefitsfromsuch programsposedbyacochranereviewandasubsequentdanishrandomizedcontrolledtrial(6,7).
7 Ferketetalperformedasystematicreviewin2010,identifyingdifferencesamongstguidelines 124 thatwouldleadtovariationsinallocationofresourcesforpreventionbetweendifferentwestern 125 healthcaresystems(8).sincethattime,thereviewedguidelineswererevisedandreplacedand 126 newevidencehasalsobecomeavailableonstatinandbloodpressureloweringtherapyinlowrisk 127 individuals(9,10).thissystematicreviewrevisitsthecvdriskassessmentguidelinesandthe 128 selectionofappropriatescreeninginterventionsbasedoncurrentlyavailableevidence
8 Methods Weconductedanupdatedsystematicreview,usingourprevioussearchstrategy(8),ofguidelines containingrecommendationsforcvdriskassessmentintheapparentlyhealthyadultpopulation notalreadyreceivingtreatmentforhighnriskcardiovascularconditionssuchasdiabetes, hypertensionandhypercholesterolemia. Datasourceandsearches Asystematicliteraturesearchwasperformedtoidentifyappropriateguidelinesfollowingthe methodsofourpreviouspublication(8).wesearchedforpublishedguidelinesusingmedlineand CINAHLbetweenMay3,2009andJune30,2016(seeAppendixforsearchstrategy).We supplementedthissearchbyusingthefollowing4guidelinesspecificdatabases;thenational GuidelineClearinghouse(US),NationalLibraryforHealthonGuidelinesFinder(UnitedKingdom), CanadianMedicalAssociationInfoBase(Canada),andGnInNInternationalGuidelineLibrary ( organizations,includingwebsitesaffiliatedwithalltheguidelinesincludedinourprevious publication,tofindadditionalorupdatedguidelinesthatwererelevant(seeappendixtable1). OursearchwasrestrictedtonationalguidelinesfromtheUnitedStates,Canada,theUnited Kingdom,AustraliaandNewZealandandtointernationalguidelineswritteninEnglish. Studyselection References that met the Institute of Medicine definition of a guideline were included. Guidelines were excluded if they (1) did not contain recommendations involving the healthy adult population, (2) were entirely focused on early detection of CVD, (3) were not produced on behalf of a professional organization, or (4) were not applicable to Western countries. In addition, only
9 guidelines produced or updated as of May 2009 were eligible for inclusion to avoid overlap with our previous systematic review and to ensure that only current guidelines were included. Dataextractionandqualityassessment Titlesandabstractswereassessedby2independentreviewers(MKandVB).Articleswereonly excludedifbothreviewersagreedtheywereineligible.discrepanciesbetweenthereviewerswere resolvedbyconsensusfollowingdiscussion.bothreviewersperformedthefinalselectionforfull dataextraction. Weusedthelatest23nitemAppraisalofGuidelinesforResearchandEvaluation(AGREE)II instrumenttodeterminetherigorofdevelopmentforeachguideline(11).therigorof developmentdomainconsidersthereportingof(1)methodstosearchforevidence,(2)criteriafor selectionofevidence,(3)strengthsandlimitationsofthebodyofevidence,(4)methodsfor formulatingtherecommendations,(5)healthbenefits,sideeffects,andrisks,(6)explicitlink betweenrecommendationsandtheevidence,(7)proceduresforexternalexpertpeerreview,and the(8)updatingprocess.eachitemisratedona7npointlikertscale.conformingtothe instructionsoftheagreeiitool,2reviewers(mkandcv)independentlyratedthe8items.both reviewersassessedbackgroundinformationontheguidelinedevelopmentprocessfrom developers websites.averagerigorscoreswereobtainedbyexpressingthesumoftheindividual scoresasapercentageofthemaximumpossiblescoreandreproducibilityofthe2reviewers scoreswasgood,withaninterclasscorrelationof0.75.werankedtheguidelinesaccordingto theirscores.editorialindependencefromthefundingbody,externalfundinganddisclosureof relationshipswithindustrybyindividualguidelinegroupmemberswerealsoassessed. Datasynthesisandanalysis
10 Onereviewer(MK)extractedalltherelevantrecommendationsfromtheguidelinesthathadan 199 AGREEIIscoreabove50%.Generallifestyleadvicewasnotincluded.Arecommendationmatrix 200 wasproducedgroupedbytheconditionsbeingdetectedbyscreening.eachmatrixwasdivided 201 into(1)amethodssection,(2)targetgroupanddeliveryofscreening,(3)recommendedscreening 202 test,and(4)thresholdsforthefollowup.consistentwithourpreviousformat,thestrengthof 203 recommendationwasclassifiedas for, consider, notfornotagainst, insufficientevidence 204 and against.iffeasiblecardiovascularriskfactorswereclassifiedintomajor,underlyingand 205 emergingriskfactorsaccordingtotheworldheartandstrokeforumscientificstatement(12) Fundingsources 208 TheworkwasprimarilyfundedaspartofaBartsCharitylargeprojectgrant.Thisworkalsoforms 209 partoftheresearchareascontributingtothetranslationalresearchportfolioofthecardiovascular 210 BiomedicalResearchUnitatBarts,whichissupportedandfundedbytheNationalInstitutefor 211 HealthResearch(SEPandMK).TheBartsCharityandtheNationalInstituteforHealthResearch 212 hadnoroleinthedesignofthestudy;thecollection,analysis,interpretationofthedata;orthe 213 decisiontoapprovepublicationofthefinishedmanuscript
11 Results Oursearchretrieved3553titles,ofwhich180wereidentifiedaspotentiallyeligible.Onthebasis 226 oftheabstracts133wereexcludedandonreviewofthefullreportsafurther26wereexcluded. 227 GuidelinessuchastheUnitedStatesPreventativeServiceTaskForce(USPSTF)guidelineson 228 aspirinusewereexcludedastheydidnotincluderecommendationsonthescreeningofhealthy 229 adultpopulation(13).finally21guidelinesoncardiovascularriskassessmentwereincluded 230 (AppendixFigure1).Table1summarizestheselectedguidelines,alongwithrigorscoreand 231 conflictsofinterest ofthe21guidelineshadarigorscoregreaterthanorequalto50%.Guidelineswere 234 categorizedaccordingtothemainpurposeofthescreening.theseincluded5guidelinesontotal 235 cardiovascularscreening(table2),7guidelinesfordysglycemiascreening(appendixtable2),2 236 guidelinesfordyslipidemiascreening(appendixtable3)and3guidelinesforhypertension 237 screening(appendixtable4) Areasofagreement 240 Recommendationsfrom16ofthe17guidelinessupportedCVDriskassessment,eitherasthe 241 primaryapproach(fiveguidelines)orasasecondarystep(elevenguidelines).ingeneraltherewas 242 consensusonhowscreeningtestsshouldbeadministeredinthegeneralpopulation.aselective 243 screeningsystembasedonknowledgeofpriorpatientcharacteristics(recordbasedscreening)or 244 duringnonnpreventivepatientvisits(casefindingoropportunisticscreening)wasadvocatedin ofthe17guidelines.twoguidelinesdidnotexplicitlyspecifyascreeningmethod(centrefor 246 DiseaseControl(CDC)/AmericanHeartAssociation(AHA)andUSPSTFhypertension)
12 Mostguidelinesrecommendedintegratingage,sex,smoking,bloodpressureandlipidlevelsinto CVDriskassessmentbyusingpredictionmodels.Howevertherewasnoconsensusonwhich predictionmodeltouse.allsevendysglycemiaguidelinesrecommendedselectingindividualsat highnriskoftype2diabetesmellitusthroughformalshortnterm(10nyear)orinformaldiabetesrisk algorithmsbasedonantecedentriskfactorsalongwiththeoftenusedthresholdof40years. Diabetesriskalgorithmswerealsousedtodecideonwhetherfurtherformaldiabetesscreening withbloodtestingwasrequired.themostcommonlymentionedriskassessmenttoolfordiabetes wasthefinlanddiabetesriskassessmentquestionnaireoramodifiedversiontailoredtothe countryimplementingit. ThemajorityofguidelinesagreedontheneedtoconsiderethnicityasariskfactorforCVDrisk andcitingspecifichighnriskethnicgroups.theunitedkingdom(nationalinstituteforhealthand ClinicalExcellence(NICE))andtheAmerican(AmericanCollegeofCardiology(ACC)/AHA) guidelinesuseethnicityinglobalcvdriskscoringalgorithms.theunitedkingdomnbasedcvdrisk score(qrisk2)calculatoradvocatedbyniceincludesmultipleethnicgroups.inthedysglycemia guidelinestheunitedkingdom,australianandcanadiandiabetesriskassessmentquestionnaires allincorporateethnicityinthepredictionoftype2diabetesonset Thereisgeneralconsensusonthelimitedroleofnovelbiomarkers(e.g.Creactiveprotein,Apo lipoproteinandprothrombinmarkers)andmarkersofsubclinicalatherosclerosis(e.g.ankle brachialindex(abi),coronaryarterycalciumscoreandcarotidultrasound).theeuropeansociety ofcardiology(esc)andacc/ahaarethetwomainguidelinesthatconsidertheuseofthese markersinlimitedsituations.theacc/ahasuggeststhatinselectedindividualswhoarenotin oneofthefourstatinbenefitgroups,andforwhomadecisiontoinitiatestatintherapyis
13 otherwiseunclear,additionalfactorsmaybeconsideredtoinformtreatmentdecisionnmaking. 273 TheseadditionalfactorsincludehighnsensitivityCnreactiveprotein>2mg/L,coronaryartery 274 calciumscore 300Agatstonunitsor 75percentileforage,sex,andethnicityandanklenbrachial 275 index<0.9.theescstatesthatroutineuseofnovelbiomarkersisnotrecommendedfor 276 refinementofcvdriskstratification.carotidatheromausingultrasound,measurementof 277 coronaryarterycalcificationandtheanklebrachialindexmaybeconsideredasariskmodifierin 278 CVDriskassessmentbutisonlyusefulinindividualsnearthresholdsforriskcategorization Thresholdsforinitiatingtreatmentarepredominantlybasedon5nor10nyearabsoluteriskforCVD 281 orbasedoncombiningageandadditionalcvdriskfactors.therewereoftenexceptionsmadefor 282 thosewithextremelevelsofasingleriskfactororthoseconsideredinahighnriskcategory(kidney 283 disease,diabetesmellitus) Aconservativeapproachtoaspirinuseinprimarypreventionistaken.Ofthe8guidelinesthat 286 makerecommendationsonaspirinuse,3donotrecommendroutineuseinprimaryprevention,3 287 ofthedysglycemiaguidelinesrecommendconsideringaspirintherapybutonlyinthepresenceof 288 additionalfactorsputtingpatientsinahighnriskcategoryandonly2guidelinesbasedthe 289 recommendationofaspirinuseonagealone.thecdc/ahaguideline,whichistheonlyguideline 290 inthisreviewthatisgenderspecific,makesrecommendationsforwomenonly,suggestsaspirin 291 useinwomenover65yearsandthecanadianhypertensioneducationprogramrecommendsits 292 useinhypertensivepatientsover55years,bothwiththecaveatthataspirinuseshouldbeguided 293 byindividualfactors.thelatestuspstfguidelineonaspirinuseinprimaryprevention,incontrast, 294 recommendsaspirinforalladultsaged50to59yearswitha10nyearcardiovasculardiseaseriskof %ormore,whoarenotatincreasedriskofbleeding,havealifeexpectancyofover10years 296 (13). 297
14 Therewasageneralconsensusontheimportanceofaddressinglifestylefactorsinalltarget groupsindependentofpharmacotherapy.recommendationsonwhoshouldreceiveintensive lifestylecounselingdifferedbetweentheguidelineswithnoconsensusbasedonglobalriskscores. Thedysglycemiaguidelinesdo,however,advocatethatallthoseathighriskfordeveloping diabetes(impairedfastingglucoseorimpairedglucosetolerance)shouldreceiveintensivelifestyle interventiontopreventtheonsetofdiabetes. Therewerenofirmstatementsregardingscreeningintervals.However,thetotalCVDrisk guidelinesadvocated5nyearlyscreeninginlowriskindividuals.recommendeddysglycemia screeningintervalsinthosewithoutevidenceofdiabeteswas3n5years.onedyslipidemia guidelinerecommended5nyearlyintervalsforadultslessthan45yearsand1n2yearlyforthose older.forthoseidentifiedashavingimpairedfastingglucoseorimpairedglucosetolerance,there wasageneralconsensusthatsubsequentannualmonitoringbeundertaken. Areasofdisagreement Therewasnoconsensusonthetargetpopulationforscreeningbetweentherecommendations. TheAmericanguidelinesfortotalcardiovascularrisk(ACC/AHA,CDC/AHA),dyslipidemia (AmericanAssociationofClinicalEndocrinologists)anddysglycemia(AmericanDiabetes Association)combinedwiththeCanadiandysglycemia(CanadianTaskForceonPreventiveHealth Care)andhypertension(CanadianHypertensionEducationProgramandCanadianTaskForceon PreventiveHealthCare)guidelinesadvocatescreeningatayoungerage(20years).TheEuropean, UnitedKingdomandAustralianguidelinesadvocateanoldertargetpopulationofover40nyear olds.
15 Althoughguidelinesmostlyagreeontheuseofriskpredictionmodelsaspartoftherisk assessmentprocessoringuidingtherapythereisnoconsensusonwhichmodeltouseparticularly withregardstototalcvdrisk.all5totalcvdriskguidelinesusedifferentriskscoresincludingthe QRISK2(NICE),SystematicCoronaryRiskEstimation(SCORE,ESC),5nyearFramingham(National VascularDiseasePreventionAlliance),PooledCohortEquation(ACC/AHA),10nyearFraminghamor Reynolds(CDC/AHA).Theseriskmodelsdifferedintheendpoints,andtheriskfactorsthey considerintheirdevelopment. Guidelinesontotalcardiovascularriskdifferregardingwhentoinitiatestatintreatment.There wasnoconsensusregardingcvdriskthresholdalthoughdirectcomparisonischallengingasall5 guidelinesuseddifferentriskpredictionmodels.themorerecentamerican(acc/aha)andunited Kingdom(NICE)recommendationsontotalcardiovascularriskhaveloweredtheirthresholdfor initiationofstatins.however,thesetwoupdatedguidelineshavealsochangedthecvdrisk equationsthattheynowutilizewhichmakesdirectcomparisontoolderthresholdsdifficultdueto differentdatasetsorendpointsthatareusedindevelopingthealgorithms.theniceguideline nowadvocatestheuseoftheqrisk2algorithmandtheacc/ahanowadvocatesthepooled CohortEquationpredictinggeneralCVDwhereaspreviouslytheybothusedtheFraminghamrisk score.the2016escguidelinehasmaintainedthesamestatinthresholdsasrecommendedinthe 2012version.Statinrecommendationsweremadein3outofthe7dysglycemiaguidelineswith onlyoneusingageover40nyearsasasoledecidingfactorinthosediagnosedwithdiabetes. Therecommendationsoninitiatingantihypertensivemedicationvariedbetweenguidelineswith noconsensusonwhatglobalriskthresholdorbloodpressureleveltouse.mostoftheguidelines
16 did,however,agreeontheimportanceofconsideringantihypertensivemedicationsindiabetic 346 patientsbutagainvariedonthebloodpressurethresholdusedtoguidethis Therewasnoconsensusontheuseoflifetimeorrelativeriskinyoungadultstoovercomethe 349 problemofusinga5to10nyeartimehorizonforpredictions.theacc/ahaadvocatetheuseof 350 lifetimerisktoguideintensivelifestyleinterventionintheyoung.theescrecommendstheuseof 351 relativeriskchartsforinformingyoungindividualsofriskwhereastheniceguidelinegenerally 352 advisesagainstusinglifetimerisktools Withregardtosubclinicalatherosclerosisscreeningteststherewasnoagreementbetweenthe 355 guidelinesregardingwhichteststouse.only2totalcvdriskguidelines(acc/ahaandesc) 356 suggestedutilizingimagingtests(coronaryarterycalciumscoringandcarotidultrasoundfor 357 atheromadetection)butthiswasonlyinselectindividualstoguidemanagementdecisions.the 358 Australianguideline(NationalVascularDiseasePreventionAlliance)wastheonlytotalCVD 359 guidelinetorecommendassessingleftventricularhypertrophyintheprimaryriskassessment
17 Discussion Weidentified21guidelines,ofwhich17wererigorouslydeveloped,oncardiovascularscreening interventionsthatcouldbeperformedwithinacardiovascularhealthcheckprogram.theaimof thissystematicreviewwasnottoprovideacomprehensiveintegrationoftheguidelinesbutrather asummaryofrigorouslydevelopednationalandinternationalguidelinesavailabletophysiciansin theformofaquickreference,whichallowseasycomparison.therewasageneralconsensuswith regardtoundertakingcvdriskscreeninganduseofpredictionmodelsforriskstratificationand guidingtreatment.theyalsoagreedontheuseofrelativelysimpleriskmarkersincludingage, gender,ethnicityandsmokinghistory.novelbiomarkersormarkersofsubclinicalatherosclerosis aregenerallynotrecommendedexceptinveryselectsubgroupofindividuals.aconservative approachtoaspirininitiationinprimarypreventionwasadvocatedandtherewasageneral agreementonintervalsforrepeatscreening.guidelinesdifferwithrespecttoselectionofthe idealtargetpopulation,whichriskpredictionmodeltouseandwhichthresholdstoutilizeto initiatestatinorantihypertensivetreatment. Weperformedabroadsearchutilizingmajormedicalpublicationrepositories,guidelinelibrary websitesandmanuallysearchingindividualguidelinedevelopmentgroupwebsites.incontrastto ourpreviouspaper,thisreviewonlysummarizesrecommendationsfromguidelines.otherreports suchaspositionandscientificstatementsarenotintheremitoftheagreeiiinstrument,and wereexcluded.alltheguidelinesincludedinthisreviewwerepublishedinthelast7yearsand representthemostrecentrecommendations.noneofthecurrent21guidelineswereincludedin ourpreviousreview.
18 Guidelinesgenerallyrecommendthatdecisionsonmanagementbebasedonglobalcardiovascular 395 riskthatconsidersmultipleriskfactors.however,theydifferregardsriskthresholdstoutilize.this 396 ispartlybecausetheriskmodelsadvocatedintheguidelinesvaryovertheuseofdatasets, 397 predictorsusedandtheirendpoints.thescoremodel(esc)usesonlyhardendpointsofcvd 398 mortalitywhereastheframingham(cdc/aha,nationalvasculardiseasepreventionalliance) 399 utilizesthebroadestendpointsconsistingofcoronarydeath,myocardialinfarction,coronary 400 insufficiency,angina,ischemicstroke,hemorrhagicstroke,transientischemicattack,peripheral 401 arterydisease,andheartfailure.furthermore,theriskthresholdforinitiatingastatinusedbythe 402 ACC/AHAof7.5%isbasedonthenewerPooledCohortEquationwhichusesthe10nyearnonnfatal 403 myocardialinfarction,coronaryheartdiseasedeath,orstrokeendpoints(18).thisvariabilitycan 404 leadtodifferentgroupsreceivingtreatment,makescomparisonbetweendifferenthealthcare 405 systemschallengingandcouldalsoleadtoinequalityofhealthcare.theaha/accguidelinesfor 406 example,wouldrecommendstatinsfornearlyallmenandtwonthirdsofwomenovertheageof nyears,exceedingtheproportionsthatwouldbeeligiblebasedonotherguidelinessuchasthe 408 ESC,whentestedinaEuropeancohort(38).Standardizationofvariousriskscoringsystems,with 409 validationandcalibration,mayhelpimproveclinicaloutcomesinindividualsatriskofdeveloping 410 CVD(39).Riskscoringsystemswouldneedtobedeveloped/updatedfordifferentcountriesdueto 411 country/regionspecificdifferencesineventratesandmortality Therearemanychallengesfacedbyprogramsthatattempttoprovidepopulationnbased 414 interventionsthatdeterminetheoverallimpactachieved.thediversityinguidelinesoncvdmay 415 partlyreflecttheuncertaintyonbenefitofscreening.althoughthereisevidencetosupportthe 416 effectivenessofparticularinterventionstoappropriateindividualsthedifficultiesinscreening 417 programsincludetheachievementofhighenoughuptakeratestoinvitations,theabilitytodeliver 418 effectiveinterventionsandpatientadherencetorecommendations. 419
19 Mostguidelinesrecommendedaselectivescreeningstrategywithsomenewerguidelines advocatingalowerthresholdforinitiatingtreatmentsuchasstatintherapy,citingrecentmetan analysisandthereducedcostsofstatinsduetopatentexpiry,asthemainreasonsforthisshift(9). Thresholdsutilizedfordecidinghighriskareoftenarbitraryandatbestdecidedonby mathematicalmodeling.studiesthatshowmodestbenefithavemainlybeenbasedon improvementsinsurrogatemarkersratherthancvdevents,withinherentlimitations(40) AMEDLINEsearchidentifiedfourprevioussystematicreviewsrelevanttoourstudy,published betweenjanuary1,2009andjune30,2016(seeappendixforsearchstrategy).twowerefromour groupincludingtheprevious(nowoutdated)versionofthisreviewandanotherfocusedon guidelinesofscreeningforperipheralvasculardiseaseonly(8,41).theremainingtwopublications werelimitedtoguidelinesonprimarycvdpreventionintheelderly(searchesuptodecember 2013)(42)orthediagnosis,assessmentandmanagementofhypertension(searchesupto September2011). Thissystematicreviewrepresentscontemporaryguidelineswithabroadinclusionofconditions eligibleforcardiovascularriskassessmentinapparentlyhealthyadultsalongwithanassessment oftheguidelinesrigorofdevelopment.comparedtoourpreviouspublicationfrom6yearsago, thetargetpopulations,riskpredictionmodelsanditsconsequencesarestillareasofdisagreement acrossguidelines(8).overthelast6yearstherehasbeenatrendtowardsadvocatingalower thresholdforinitiatingintensivelifestylemodificationandstatintherapy.riskpredictionmodels havebeenupdatedwithamoveawayfromtheframinghamriskscore,whichpreviously predominated.thereisamoreconservativeapproachtoaspirin,withmostguidelinesgenerally advocatingagainstitsuseinprimaryprevention.theuseoftestsforassessmentofsubclinical
20 atherosclerosishasbeenfurtherrestricted Theoptimalstrategyforsystematicscreeningfortheapparentlyhealthyremainstobeanswered. Someadvocatecontinuingwiththecurrentstrategyofscreeningwiththeaimoftryingtomoldit intoasystemthateventuallyshowsbenefitwhereasothersareaskingfortheprogramstobe halteduntilsuchatimethattheevidenceofbenefitjustifiestheresourcesinvestedinscreening (43,44).Recentpublicationsaddressingsomeofthesegapsandfutureresearchinidentifyingthe mosteffectivestrategieswillhelpshapefutureguidelinerecommendations(45n47) Therearesomelimitationsthatcouldbiasourfindingsandlimitgeneralizability.Onlyguidelines developedbywesternnationalorinternationalmedicalorganizationswerereviewed.we controlledforselectionbiasbyhavingacomprehensivesearchstrategy,aspreviouslygenerated withalibrarianandthearticleswereselectedandappraisedbytwoindependentresearchers. However,researcherswerenotblindedtotheorganizationnamesorcountriesoforigin.Finally, weconsideredtheguidelinedevelopmentprocessbutdidnotassesstheclinicalvalidityofthe recommendationorreviewrecommendationsforspecificlifestyleinterventionsasitwasbeyond thescopeofthisreview
21 Conclusion Considerablediscrepanciesinrecommendationsstillexistincardiovascularscreeningguidelines 469 withnoconsensusonoptimumscreeningstrategiesortreatmentthreshold.physiciansshould 470 assessthestrengthoftherecommendationsandthelevelofevidencetodecidewhichofthe 471 discrepantrecommendationstheymayimplement Endofmanuscripttext
22 Acknowledgements ProfessorHuninkreceivesroyaltiesforthetextbook:DecisionMakinginHealthandMedicine: IntegratingevidenceandvaluesnMyriamHuninkwithCambridgeUniversityPress.Theother authorshavenopotentialconflictsofinteresttodeclare. GrantSupport LargeprojectgrantfromtheBartsCharityfortheHeartAttackPreventionProgramForYou (HAPPY)LondonStudyGrantreferencenumber437/1412. Addressforreprintrequest M.G.MyriamHunink,MD,PhD RoomNa2818 ErasmusMC POBox2040,3000CA,Rotterdam,TheNetherlands Tel: /Fax: addressesforauthors MohammedY.Khanji,MBBCh; ViníciusV.S.Bicalho,MD; ClaudiaN.vanWaardhuizen,MSc; BartS.Ferket,PhD; SteffenE.Petersen,DPHIL; M.G.MyriamHunink,PhD (correspondingauthor)
23 ReproducibleResearchStatement 517 StudyProtocol:Notavailable 518 StatisticalCode:Notapplicable 519 DataSet:Seetablesandappendices.Otherinformation(e.g.listofexcludedarticlesavailableon 520 requestfromauthors)
24 References 1. RechelB,DoyleY,GrundyE,McKeeM.Howcanhealthsystemsrespondtopopulation ageing?2009.worldhealthorganizationeurope; data/assets/pdf_file/0004/64966/e92560.pdf.lastaccessedjuly26, InstituteofMedicine(US)CommitteeonStandardsforDevelopingTrustworthyClinical PracticeGuidelines,GrahamR,MancherM,MillerWolmanD,GreenfieldS,SteinbergE. ClinicalPracticeGuidelinesWeCanTrust.Washington(DC):NationalAcademiesPress(US); KotsevaK,WoodD,DeBacquerD,DeBackerG,RydenL,JenningsC,etal.EUROASPIREIV: AEuropeanSocietyofCardiologysurveyonthelifestyle,riskfactorandtherapeutic managementofcoronarypatientsfrom24europeancountries.eurjprevcardiol.2016 Apr;23(6): DallongevilleJ,BanegasJR,TubachF,GuallarE,BorghiC,DeBackerG,etal.Surveyof physicians'practicesinthecontrolofcardiovascularriskfactors:theeurikastudy.eurj PrevCardiol.2012Jun;19(3): CapewellS,McCartneyM,HollandW.NHSHealthChecksnnanakedemperor?JPublic Health(Oxf).2015Jun;37(2): KrogsbøllLT,JørgensenKJ,GrønhøjLarsenC,GøtzschePC.Generalhealthchecksinadults forreducingmorbidityandmortalityfromdisease:cochranesystematicreviewandmetan analysis.bmj.2012;345(nov203):e JørgensenT,JacobsenRK,ToftU,AadahlM,GlümerC,PisingerC.Effectofscreeningand lifestylecounsellingonincidenceofischaemicheartdiseaseingeneralpopulation:inter99 randomisedtrial.bmj.2014;348(jun092):g FerketBS,ColkesenEB,VisserJJ,SpronkS,KraaijenhagenRA,SteyerbergEW,etal. Systematicreviewofguidelinesoncardiovascularriskassessment:Whichrecommendations shouldcliniciansfollowforacardiovascularhealthcheck?archinternmed.2010jan 11;170(1): CholesterolTreatmentTrialists'(CTT)Collaborators,MihaylovaB,EmbersonJ,BlackwellL, KeechA,SimesJ,etal.TheeffectsofloweringLDLcholesterolwithstatintherapyinpeople atlowriskofvasculardisease:metananalysisofindividualdatafrom27randomisedtrials. Lancet.2012Aug11;380(9841): BloodPressureLoweringTreatmentTrialists'Collaboration,SundströmJ,ArimaH, WoodwardM,JacksonR,KarmaliK,etal.Bloodpressurenloweringtreatmentbasedon cardiovascularrisk:ametananalysisofindividualpatientdata.lancet.2014aug 16;384(9943): BrouwersMC,KhoME,BrowmanGP,BurgersJS,CluzeauF,FederG,etal.AGREEII: advancingguidelinedevelopment,reportingandevaluationinhealthcare.cmaj.2010dec 14;182(18):E
25 SmithSC,JacksonR,PearsonTA,FusterV,YusufS,FaergemanO,etal.Principlesfor nationalandregionalguidelinesoncardiovasculardiseaseprevention:ascientificstatement fromtheworldheartandstrokeforum.vol.109,circulation.2004.pp BibbinsnDomingoK,U.S.PreventiveServicesTaskForce.AspirinUseforthePrimary PreventionofCardiovascularDiseaseandColorectalCancer:U.S.PreventiveServicesTask ForceRecommendationStatement.AnnInternMed.AmericanCollegeofPhysicians;2016 Jun21;164(12): NationalClinicalGuidelineCentre(UK),NationalClinicalGuidelineCentre(UK).Lipid Modification:CardiovascularRiskAssessmentandtheModificationofBloodLipidsforthe PrimaryandSecondaryPreventionofCardiovascularDisease.London:NationalInstitutefor HealthandCareExcellence(UK);2014Jul. July26, PiepoliMF,HoesAW,AgewallS,AlbusC,BrotonsC,CatapanoAL,etal.2016European Guidelinesoncardiovasculardiseasepreventioninclinicalpractice:TheSixthJointTask ForceoftheEuropeanSocietyofCardiologyandOtherSocietiesonCardiovascularDisease PreventioninClinicalPractice(constitutedbyrepresentativesof10societiesandbyinvited experts):developedwiththespecialcontributionoftheeuropeanassociationfor CardiovascularPreventionRehabilitation(EACPR).EurHeartJ.2016May NationalVascularDiseasePreventionAlliance.GuidlinesfortheManagementofAbsolute CardiovascularDiseaseRisk.2012May23;: Guidelines.pdf.LastaccessedJuly26, NeilJStoneMMFF,JenniferRobinsonMMF,AliceHLichtensteinDF,CNoelBaireyMerz MFF,DonaldMLloydnJonesMSFF,ConradBBlumMF,etal.2013ACC/AHAGuidelineonthe TreatmentofBloodCholesteroltoReduceAtheroscleroticCardiovascularRiskinAdults. JournaloftheAmericanCollegeofCardiology.ElsevierLtd;2013Nov7;63(25): GoffDC,LloydnJonesDM,BennettG,CoadyS,D'AgostinoRB,GibbonsR,etal.2013 ACC/AHAguidelineontheassessmentofcardiovascularrisk:areportoftheAmerican CollegeofCardiology/AmericanHeartAssociationTaskForceonPracticeGuidelines.Vol. 63,JournaloftheAmericanCollegeofCardiology.2014.pp EckelRH,JakicicJM,ArdJD,deJesusJM,HoustonMillerN,HubbardVS,etal.2013 AHA/ACCguidelineonlifestylemanagementtoreducecardiovascularrisk:areportofthe AmericanCollegeofCardiology/AmericanHeartAssociationTaskForceonPractice Guidelines.Vol.63,JournaloftheAmericanCollegeofCardiology.2014.pp MoscaL,BenjaminEJ,BerraK,BezansonJL,DolorRJ,LloydnJonesDM,etal.Effectivenessn basedguidelinesforthepreventionofcardiovasculardiseaseinwomennn2011update:a guidelinefromtheamericanheartassociation.vol.57,journaloftheamericancollegeof Cardiology.2011.pp JBS3Board.JointBritishSocieties'consensusrecommendationsforthepreventionof cardiovasculardisease(jbs3).vol.100suppl2,heart(britishcardiacsociety).2014.pp.ii1 ii67.
26 GroupNZG.NewZealandPrimaryCareHandbook Jan24;: handbookn2012.pdf.lastaccessedjuly26, EuropeanAssociationforCardiovascularPreventionRehabilitation,ReinerŽ,Catapano AL,DeBackerG,GrahamI,TaskinenMnR,etal.ESC/EASGuidelinesforthemanagementof dyslipidaemias:thetaskforceforthemanagementofdyslipidaemiasoftheeuropean SocietyofCardiology(ESC)andtheEuropeanAtherosclerosisSociety(EAS).Vol.32, Europeanheartjournal.2011.pp JellingerPS,SmithDA,MehtaAE,GandaO,HandelsmanY,RodbardHW,etal.American AssociationofClinicalEndocrinologists'GuidelinesforManagementofDyslipidemiaand PreventionofAtherosclerosis.Vol.18Suppl1,Endocrinepractice:officialjournalofthe AmericanCollegeofEndocrinologyandtheAmericanAssociationofClinical Endocrinologists.2012.pp AndersonTJ,GrégoireJ,HegeleRA,CoutureP,ManciniGBJ,McPhersonR,etal.2012 updateofthecanadiancardiovascularsocietyguidelinesforthediagnosisandtreatmentof dyslipidemiaforthepreventionofcardiovasculardiseaseintheadult.canjcardiol.2013 Feb;29(2): NationalEvidenceBasedGuidelineforthePrimaryPreventionofType2Diabetes.2010Jan 20;: n403anbd2dn44a241bb9189.pdf.LastaccessedJuly26, CanadianDiabetesAssociationClinicalPracticeGuidelinesExpertCommittee,BoothG, ChengAYY.CanadianDiabetesAssociation2013clinicalpracticeguidelinesforthe preventionandmanagementofdiabetesincanada.methods.vol.37suppl1,canadian JournalofDiabetes.2013.pp.S AssociationAD.StandardsofMedicalCareinDiabetesn2016:SummaryofRevisions. DiabetesCare.AmericanDiabetesAssociation;2016Jan;39Suppl1(Supplement1):S SiuAL,U.S.PreventiveServicesTaskForce.ScreeningforAbnormalBloodGlucoseandType 2DiabetesMellitus:U.S.PreventiveServicesTaskForceRecommendationStatement.Vol. 163,Annalsofinternalmedicine.AmericanCollegeofPhysicians;2015.pp Preventingtype2diabetes:riskidentificationandinterventionsforindividualsathighrisk. 2013Nov22;: PottieK,JaramilloA,LewinG,DickinsonJ,BellN,BrauerP,etal.Recommendationson screeningfortype2diabetesinadults.cmaj.2012;184(15): Authors/TaskForceMembers,RydenL,GrantPJ,AnkerSD,BerneC,CosentinoF,etal.ESC Guidelinesondiabetes,prendiabetes,andcardiovasculardiseasesdevelopedin collaborationwiththeeasd:thetaskforceondiabetes,prendiabetes,andcardiovascular diseasesoftheeuropeansocietyofcardiology(esc)anddevelopedincollaborationwith theeuropeanassociationforthestudyofdiabetes(easd).vol.34,europeanheartjournal pp InternationalDiabetesFederationGuidelineDevelopmentGroup.Globalguidelinefortype
27 diabetes.Vol.104,DiabetesResearchandClinicalPractice.2014.pp DasguptaK,QuinnRR,ZarnkeKB,RabiDM,RavaniP,DaskalopoulouSS,etal.The2014 CanadianHypertensionEducationProgramrecommendationsforbloodpressure measurement,diagnosis,assessmentofrisk,prevention,andtreatmentofhypertension. CanJCardiol.2014May;30(5): DaskalopoulouSS,RabiDM,ZarnkeKB,DasguptaK,NerenbergK,CloutierL,etal.The2015 canadianhypertensioneducationprogramrecommendationsforbloodpressure measurement,diagnosis,assessmentofrisk,prevention,andtreatmentofhypertension. CanJCardiol.2015May;31(5): SiuAL,U.S.PreventiveServicesTaskForce.Screeningforhighbloodpressureinadults:U.S. PreventiveServicesTaskForcerecommendationstatement.Vol.163,Annalsofinternal medicine.americancollegeofphysicians;2015.pp LindsayP,GorberSC,JoffresM,BirtwhistleR,McKayD,CloutierL.Recommendationson screeningforhighbloodpressureincanadianadults.canfamphysician.2013 Sep;59(9): KavousiM,LeeningMJG,NanchenD,GreenlandP,GrahamIM,SteyerbergEW,etal. ComparisonofapplicationoftheACC/AHAguidelines,AdultTreatmentPanelIIIguidelines, andeuropeansocietyofcardiologyguidelinesforcardiovasculardiseasepreventionina Europeancohort.JAMA.2014Apr9;311(14): SarafS,RayKK.Newworldwidelipidguidelines.CurrentOpinioninCardiology.2015Jul 1;30(4): SiS,MossJR,SullivanTR,NewtonSS,StocksNP.Effectivenessofgeneralpracticenbased healthchecks:asystematicreviewandmetananalysis.brjgenpract.2014 Jan;64(618):e FerketBS,SpronkS,ColkesenEB,HuninkMGM.Systematicreviewofguidelineson peripheralarterydiseasescreening.amjmed.2012feb;125(2): e JansenJ,McKinnS,BonnerC,IrwigL,DoustJ,GlasziouP,etal.Systematicreviewofclinical practiceguidelinesrecommendationsaboutprimarycardiovasculardiseasepreventionfor olderadults.bmcfampract.biomedcentral;2015;16(1): LauritzenT,SandbaekA,BorchnJohnsenK.Generalhealthchecksmaywork.BMJ. 2014;349(jul304):g GøtzschePC,JørgensenKJ,KrogsbøllLT.Generalhealthchecksdon'twork.BMJ. 2014;348(jun094):g YusufS,LonnE,PaisP,BoschJ,LópeznJaramilloP,ZhuJ,etal.BloodnPressureand CholesterolLoweringinPersonswithoutCardiovascularDisease.NEnglJMed.2016May 26;374(21): YusufS,BoschJ,DagenaisG,ZhuJ,XavierD,LiuL,etal.CholesterolLoweringin IntermediatenRiskPersonswithoutCardiovascularDisease.NEnglJMed.2016May 26;374(21):
28 47. LonnEM,BoschJ,LópeznJaramilloP,ZhuJ,LiuL,PaisP,etal.BloodnPressureLoweringin 708 IntermediatenRiskPersonswithoutCardiovascularDisease.NEnglJMed.2016May ;374(21):
29 Table 1. Characteristics of 21 Guidelines Guideline by Medical Condition, year Organization Responsible for Guideline Development Total Cardiovascular risk Country Applied AGREE2 Rigor score, % Conflicts of Interest NICE (14), 2014 National Institute for Health and Clinical UK 86 EI,SCI* Excellence ESC (15), 2012 European Society of Cardiology Europe 86 SCI * NVDPA (16), 2012 National Vascular Disease Prevention Alliance Australia 85 EI,SCI ACC/AHA (17-19), American College of Cardiology United States 83 SCI * 2013 CDC (20), 2011 Centres for Disease Control and Prevention United States 65 EI,SCI * BCS (21), 2014 British Cardiovascular Society UK 45 SCI * NZGG (22), 2012 New Zealand Guidelines Group New Zealand 20 EI,SCI Dyslipidemia ESC (23), 2011 European Society of Cardiology Europe 72 SCI * ACCE (24), 2012 American Association of Clinical United States 64 SCI * Endocrinologists CCS (25), 2013 Canadian Cardiovascular society Canada 42 EI,SCI * Dysglycemia ADS/DAGDC (26), 2009 Australian Diabetes Society Australia 87 SCI CDA (27), 2013 Canadian Diabetes Association Canada 83 EI,FIP,SCI * ADA (28), 2014 American Diabetes Association United States 68 SCI * USPSTF (29), 2015 U.S. Preventative Services Task Force United States 76 EI, SCI NICE (30), 2012 National Institute for Health and Clinical UK 73 Excellence CTFPHC (31), 2012 Canadian Task Force on Preventive Health Canada 68 EI,SCI * Care ESC (32), 2013 European Society of Cardiology Europe 66 SCI * IDF (33), 2012 International Diabetes Federation International 47 FIP, SCI Hypertension CHS (34,35), 2015 Canadian Hypertension Society Canada 90 EI,SCI * USPSTF (36),2015 U.S. Preventative Services Task Force United States 79 EI, SCI CTFPHC (37), 2013 Canadian Task Force on Preventive Health Care Abbreviations: AGREE2, Appraisal of Guidelines Research and Evaluation II; EI, editorial; independence declared; FIP, funding by industrial partner reported; SCI, statement about conflicts of interest of group members present; UK, United Kingdom *Relationship with industry is reported by any group member; A group member is reported recused when a relevant area is under discussion; Conflicts of interest only available on request; Conflicts of interest only reported to the group Canada 78 SCI
30 Table 2. Recommendations for Screening in Total CVD Risk in 5 Guidelines ESC NICE NVDPA ACC/ AHA CDC/ AHA Country Europe UK Australia USA USA Year AGREE 2 Score 86% 86% 85% 83% 65% Method to evaluate Systematic review Systematic Systematic Systematic Systematic evidence Methods to formulate recommendations Consideration of costs Formal consensus Review of CEA studies Target Group Men > 40 y, Women >50 y or post menopausal Strategy Strength of recommendation Major risk factors prediction model Opportunistic screening/ case finding review Formal consensus Systematic review of published literature/ Performed CEA Aged (NHS Health Check) Opportunistic screening/ case finding/ record based review Formal consensus Review of CEA studies All adults aged >45 y or Aboriginal Torres Strait Islanders >35y Opportunistic screening/ case finding review Formal consensus Not performed Aged 21 and above Opportunistic screening/ case finding review Formal consensus and voting Review of CEA studies Women 20 y For For For For Not for and not against SCORE, general QRISK2, Framingham, ASCVD mortality CHD/stroke/TIA CHD/stroke at 10 y events at 10 y events at 5 y Pooled Cohort Equations, CHD/stroke events at 10 y if age y or lifetime (30 y) risk for y with 10 y risk 7.5% Age Sex Blood pressure TC level LDL-C level HDL-C level TC:HDL-C ratio Smoking Glucose levels 2 2 Underlying risk factors Overweight/obesity Physical inactivity Atherogenic diet Socioeconomic factors Family history of premature CVD Genetic/racial factors Diabetes Antihypertensives Emerging risk factors TG levels Renal function NR Framingham/ Reynolds Risk Score, CHD/stroke at 10 y
31 Table 2. Recommendations for Screening in Total CVD Risk in 5 Guidelines (continued). ESC NICE NVDPA ACC/ AHA CDC/ AHA Heart rate 2 Apo/lipoprotein levels 4 Glucose therapy for insulin resistance Prothrombotic markers 4 C-reactive protein level 4 3 Subclinical atherosclerosis 1 (LVH) 3 (ABI, CAC score) Thresholds Aspirin Statins Antihypertensives Intensive Lifestyle Counseling 4 (ABI, CAC score, carotid US for plaque) Not recommended in primary prevention 10 y CVD mortality 10% and LDL-C level 70 mg/dl; 10 y risk 5%-10% and LDL-C level 100 mg/dl; consider if 10 y risk <5% and LCL-C >115mg/dL; DM2 or DM1 and age >40 y 10 y CVD mortality 10% and BP 140/90 mmhg; consider if 10 y risk 5-10% and BP 140/90 mmhg; DM1 or DM2 and BP 140/85 mmhg; over 60 y and systolic BP >150mmHg or more than 80 y and systolic BP >160mmHg; BP 180/110 mmhg 10 y CVD mortality >1% or LDL-C >100mg/dL Not applicable 10 y CHD/stroke/TIA risk 10%; DM2 and 10 y CVD risk 10% (according to UKPDS tool); DM1; CKD with egfr <60 Not recommended in primary prevention 5 y CHD/stroke risk 15%; persistent BP 160/100 mmhg; TC >7.5mmol/L; 5 y CHD/stroke risk 10%-15% and family history of premature CVD NR 5 y FRS 15%; FRS 10-15% and BP persistently 160/100/ FHx CVD, high risk ethnicity; consider if FRS <10% but BP persistently 160/100 mmhg 10 y CHD/stroke/TIA risk 10% 5 y CHD/stroke risk 10%. Not applicable y with 10 y CHD/stroke risk 7.5% and LDL-C mg/dl; y with DM and LDL-C mg/dL; LDL-C level 190 mg/dl Useful in women 65 depending on risk benefit; reasonable in DM 10 y risk >20%; DM NR BP 140/90 mmhg; >130/85 in CKD and DM 10 y CHD/ stroke risk 7.5% and LDL-C mg/dl; DM1 or DM2; LDL-C level 190 mg/dl NR
32 Table 2. Recommendations for Screening in Total CVD Risk in 5 Guidelines (continued). ESC NICE NVDPA ACC/ AHA CDC/ AHA High-risk Monitoring NR NR Monitor risk NR NR profile according to clinical context if 5 y CHD/stroke risk 15%. Monitor risk profile every 6-12 months if 5 y CHD/stroke risk 10-15% Screening Intervals NR Further risk assessment on an on going basis. 5 yearly as per NSF Further risk assessment every 2 y if 5 y CHD/stroke risk <10% Further risk assessment every 4-6 y if 10 y CHD/stroke risk <7.5% NR Abbreviations: ABI, ankle brachial index; ASCVD, atherosclerotic cardiovascular disease; CEA, costeffectiveness analysis; CAC, coronary artery calcium; CHD, coronary heart disease; CKD, chronic kidney disease; CVD, cardiovascular disease; DM - diabetes mellitus; FHx, family history; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; LVH, left ventricular hypertrophy; NHS, National Health Service; NR, not reported; NSF, National Service Framework; SCORE, Systematic Coronary Risk Evaluation; TC, total cholesterol; TG, triglyceride; TIA, transient ischemic attack; UK, United Kingdom; US, ultrasound; y, years; 1, Formal screening test (included in the prediction model); 2, Additional screening test 3, In selected individuals who are not in 1 of the 4 main statin benefit groups, and for who a decision to initiate statin therapy is otherwise unclear, additional factors may be considered to inform treatment decision-making. These factors include; 1. Primary LDL C 160 mg/dl or other evidence of genetic hyperlipidemias, 2. First degree relative with premature ASCVD, 3. Highsensitivity C-reactive protein >2 mg/l, 4. CAC score 300 Agatston units or 75 percentile for age, sex, and ethnicity, 5. Ankle-brachial index <0.9, or 6. Elevated lifetime risk of ASCVD. 4, Novel biomarkers have only limited additional value when added to CVD risk assessment with the SCORE algorithm in come limited cases.
33 Appendix Table 1: Website searches of guideline development organizations, including websites affiliated with all the guidelines included in our previous publication Organization Responsible for Country Website Searched Guideline Development American Academy of Family United States Physicians (AAFP) American Association of Clinical United States Endocrinologists American College of Cardiology United States American College of Physicians United States American College for United States Preventive Medicine American Diabetes Association United States (ADA) American Geriatrics Society United States (AGS) American Heart Association United States (AHA) American Medical Association United States (AMA) American Stroke Association United States Australian Diabetes Society Australia (ADS) Australian Medical Association Australia (AMA) British Cardiac Society (BCS) United Kingdom British Hypertension Society United Kingdom (BHS) Canadian Diabetes Association Canada Canadian Hypertension Society Canada (CHS) Canadian Task Force on Canada Preventive Health Care (CTFPHC) Cardiac Society of Australia and Australia New Zealand (CSANZ) Centers for Disease Control and United States Prevention (CDC)/ AHA Department of Health (DOH) United Kingdom European Society of Cardiology Europe International Diabetes International Federation (IDF) International Society of International Hypertension National Health and Medical Australia Research Council (NHMRC) National Heart Foundation Australia National Heart Lung and Blood United States Institute National Institute for Health United Kingdom and Clinical Excellence (NICE) New Zealand Guidelines Group New Zealand Royal College of General Practitioners (RCGP) United Kingdom
New Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationLatest Guidelines for Lipid Management
Latest Guidelines for Lipid Management Goals Recognize the differences between different guidelines Understand the effective strategies to tailor lipid lowering therapies based on evidence and guideline
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationNew Guidelines in Dyslipidemia Management
The Third IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2017 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationREVIEW ARTICLE. (CVD) is the leading cause. total mortality. 1 Much of the burden of CVD can potentially be relieved by primary prevention,
REVIEW ARTICLE Review of Guidelines on Cardiovascular Risk Assessment Which Recommendations Should Clinicians Follow for a Cardiovascular Health Check? Bart S. Ferket, MD; Ersen B. Colkesen, MD; Jacob
More informationNEW GUIDELINES FOR CHOLESTEROL
NEW GUIDELINES FOR CHOLESTEROL NEW CHOLESTEROL GUIDELINES 2013 Recently updated guidelines for the treatment of high blood cholesterol levels is a major update since 2002. The news media have trumpeted
More informationACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS
ACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS Ziyad Ghazzal MD, FACC, FSCAI Professor of Medicine Deputy Vice President/Dean Associate Dean for Clinical Affairs American University of Beirut Adjunct
More informationCVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic
CVD Risk Assessment Michal Vrablík Charles University, Prague Czech Republic What is Risk? A cumulative probability of an event, usually expressed as percentage e.g.: 5 CV events in 00 pts = 5% risk This
More informationUpdate on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines
Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines Paul Mahoney, MD Sentara Cardiology Specialists Lipid Management in Cardiovascular Disease
More informationReview current guideline recommendations for lipid-lowering therapy
Breakout Session #3 New Paradigms in the Management of Dyslipidemia Review current guideline recommendations for lipid-lowering therapy Dr Meral KAYIKCIOGLU Ege University Medical School, Cardiology Dept,
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More information2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary
2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease Becky McKibben, MPH; Seth
More informationTreatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
More informationCVD Prevention, Who to Consider
Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..
More informationAn update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine
An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal
More informationLipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice
Lipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice Vera Bittner, MD, MSPH Professor of Medicine Section Head, Preventive Cardiology Medical Director, Cardiac Rehabilitation
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationConflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines
Conflict of Interest Disclosure Updates for the Ambulatory Care Pharmacist: Dyslipidemia and CV Risk Assessment No conflicts of interest to disclose 2014 Updates to the Updates in Ambulatory Care Pharmacy
More informationAssessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution
CLINICAL Viewpoint Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients Copyright Not for Sale or Commercial Distribution By Ruth McPherson, MD, PhD, FRCPC Unauthorised
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationDavid Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon
David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon I have no actual or potential conflicts of interest in relation to this program or presentation. Raphael School of Athens, 1509-1511 Apply
More informationThe Art of Cardiovascular Risk Assessment
The Art of Cardiovascular Risk Assessment Laurence S. Sperling, M.D., FACC, FACP,FAHA, FASPC Professor of Medicine (Cardiology) Professor of Global Health Director- Center for Heart Disease Prevention
More informationAcute Coronary Syndromes (ACS)
Sally A. Arif, Pharm.D., BCPS (AQ Cardiology) Assistant Professor of Pharmacy Practice Midwestern University, Chicago College of Pharmacy Cardiology Clinical Specialist, Rush University Medical Center
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationYoung high risk patients the role of statins Dr. Mohamed Jeilan
Young high risk patients the role of statins Dr. Mohamed Jeilan KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures
More informationSupplementary Online Content
Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines
More informationUnderstanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s
Understanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s Ho Chi Minh City, Vietnam August 7, 2014 JBS 2 Risk Guidelines (2005) Based
More informationObservations on US CVD Prevention Guidelines. Donald M. Lloyd-Jones, MD ScM FACC FAHA
Observations on US CVD Prevention Guidelines Donald M. Lloyd-Jones, MD ScM FACC FAHA What are Guidelines? Evidence Base for Guidelines Tricoci, JAMA 2009 Evidence Base for Guidelines Tricoci, JAMA 2009
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationModule 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension
Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationDiabetes and Heart Disease. Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center
Diabetes and Heart Disease Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center No conflicts of interest or financial relationships to disclose. 2 What s the problem??
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationUsing Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly
Using Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly Paul Muntner, PhD MHS Professor and Vice Chair Department of Epidemiology University of Alabama
More informationIdentification of subjects at high risk for cardiovascular disease
Master Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April 14 2011 Identification of subjects at high risk for cardiovascular disease Lars Rydén Karolinska Institutet
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationTotal risk management of Cardiovascular diseases Nobuhiro Yamada
Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible
More informationCalculating Risk for Primary Prevention of Cardiovascular Disease (CVD)
Calculating Risk for Primary Prevention of Cardiovascular Disease (CVD) 2. Welcome by Stacey Sheridan, MD, MPH Hello. My name is Stacey Sheridan, and I m here as your partner in Heart Health Now. The North
More informationCurrent Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD
Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center
More informationLIPID GUIDELINES: 2015
LIPID GUIDELINES: 2015 D P Mikhailidis BSc MSc MD FCPP FCP FRSPH FFPM FRCP FRCPath Academic Head Dept. of Clinical Biochemistry (Vascular Disease Prevention Clinics) Royal Free campus University College
More informationEyes on Korean Data: Lipid Management in Korean DM Patients
Eyes on Korean Data: Lipid Management in Korean DM Patients ICDM Luncheon Symposium Sung Rae Kim MD PhD Division of Endocrinology and Metabolism The Catholic University of Korea Causes of Death in People
More informationWelcome and Introduction
Welcome and Introduction This presentation will: Define obesity, prediabetes, and diabetes Discuss the diagnoses and management of obesity, prediabetes, and diabetes Explain the early risk factors for
More informationPrevention Updates and Paradigm Shifts
Prevention Updates and Paradigm Shifts Andrew Freeman, MD, FACC Director of Clinical Cardiology and Operations National Jewish Health Assistant Professor of Medicine National Jewish Health and University
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Primary prevention of CVD Potential output:
More informationMOHAMMED R. ESSOP DIVISION OF CARDIOLOGY CH-BARAGWANATH HOSPITAL
MOHAMMED R. ESSOP DIVISION OF CARDIOLOGY CH-BARAGWANATH HOSPITAL DEFINITION OF A SCREENING TEST TESTING FOR A DISEASE OR CONDITION IN ASYMPTOMATIC PERSONS TO IDENTIFY THE CONDITION BEFORE IT MANIFESTS
More informationAbsolute cardiovascular disease risk management
Quick reference guide for health professionals Absolute cardiovascular disease risk management This quick reference guide is for use by health professionals for primary prevention of cardiovascular disease
More informationCardiovascular Diseases in CKD
1 Cardiovascular Diseases in CKD Hung-Chun Chen, MD, PhD. Kaohsiung Medical University Taiwan Society of Nephrology 1 2 High Prevalence of CVD in CKD & ESRD Foley RN et al, AJKD 1998; 32(suppl 3):S112-9
More information9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.
UW MEDICINE UW MEDICINE UCSF ASIAN TITLE HEALTH OR EVENT SYMPOSIUM 2017 DISCLOSURES Consultant: RubiconMD ESTIMATING CV RISK IN ASIAN AMERICANS AND PREVENTION OF CVD Research: Amgen, NHLBI EUGENE YANG,
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu Indicator area: Pulse rhythm assessment for AF Indicator: NM146 Date: June 2017 Introduction There is evidence
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationCARDIOMETABOLIC SYNDROME
CARDIOMETABOLIC SYNDROME Prof. Gerald Yonga FESC, FACC Dept of Medicine, Aga Khan University East Africa Introduction Years after the term metabolic syndrome was first coined, controversy continues over
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationLearning Objectives. Patient Case
Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations
More information4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?
HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationReducing Cardiovascular Risk in Adults. ACC Guidelines for Cholesterol Reduction: NCEP ATP CAOM Winter Seminar
Reducing Cardiovascular Risk in Adults ACC Guidelines for Cholesterol Reduction: NCEP ATP4 2014 CAOM Winter Seminar A Roadmap: Defining the Problem, Implementing Solutions Discuss U.S. Healthcare costs,
More informationDiabetes and Heart Disease
Diabetes and Heart Disease Sarah Alexander, MD Assistant Professor of Medicine Division of Cardiology Rush University Medical Center 2/8/2017 Rush is a not-for-profit health care, education and research
More informationBlood Pressure LIMBO How Low To Go?
Blood Pressure LIMBO How Low To Go? Joseph L. Kummer, MD, FACC Bryan Heart Spring Conference April 21 st, 2018 Hypertension Epidemiology Over a billion people have hypertension Major cause of morbidity
More information2016 EUROPEAN GUIDELINES ON CVD PREVENTION IN CLINICAL PRACTICE
2016 EUROPEAN GUIDELINES ON CVD PREVENTION IN CLINICAL PRACTICE Massimo F Piepoli, MD, PhD, FESC, Piacenza, Italy on behalf of the 6 th Joint Task Force 2 3 Guidelines still based upon the principles of
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationHypertension Guidelines 2017
Hypertension Guidelines 2017 (American College of Cardiology and the American Heart Association) In 1977, the 1st comprehensive guideline for detection, evaluation, and management of high BP was published,
More informationAppendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.
Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular
More information2013 Hypertension Measure Group Patient Visit Form
Please complete the form below for 20 or more unique patients meeting patient sample criteria for the measure group for the current reporting year. A majority (11 or more) patients must be Medicare Part
More informationAtherosclerotic Disease Risk Score
Atherosclerotic Disease Risk Score Kavita Sharma, MD, FACC Diplomate, American Board of Clinical Lipidology Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics September 16,
More informationUse of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease
Accepted Manuscript Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease Donald M. Lloyd-Jones, MD, ScM, FACC, FAHA, Lynne T. Braun,
More informationPrevention of Heart Disease: The New Guidelines
Prevention of Heart Disease: The New Guidelines Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California San Francisco May 18 th 2015
More informationCONTRIBUTING FACTORS FOR STROKE:
CONTRIBUTING FACTORS FOR STROKE: HYPERTENSION AND HYPERCHOLESTEROLEMIA Melissa R. Stephens, MD, FAAFP Associate Professor of Clinical Sciences William Carey University College of Osteopathic Medicine LEARNING
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationLipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute
Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationCARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES
CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES C. Liakos, 1 G. Vyssoulis, 1 E. Karpanou, 2 S-M. Kyvelou, 1 V. Tzamou, 1 A. Michaelides, 1 A. Triantafyllou, 1 P. Spanos, 1 C. Stefanadis
More informationDisclosures. Prevention of Heart Disease: The New Guidelines. Summary of Talk. Four guidelines. No relevant disclosures.
Disclosures Prevention of Heart Disease: The New Guidelines No relevant disclosures Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California
More informationThe recently released American College of Cardiology
Data Report Atherosclerotic Cardiovascular Disease Prevention A Comparison Between the Third Adult Treatment Panel and the New 2013 Treatment of Blood Cholesterol Guidelines Andre R.M. Paixao, MD; Colby
More informationPharmacy Drug Class Review
Pharmacy Drug Class Review January 22, 2014 Authored By: Christina Manciocchi, Pharm.D. BCACP Disclaimer: Specific agents may have variations Edited By: Richard J. Kraft, Pharm.D.BCPS NEW CHOLESTEROL GUIDELINES
More informationWhich CVS risk reduction strategy fits better to carotid US findings?
Which CVS risk reduction strategy fits better to carotid US findings? Dougalis A, Soulaidopoulos S, Cholongitas E, Chalevas P, Vettas Ch, Doumtsis P, Vaitsi K, Diavasti M, Mandala E, Garyfallos A 4th Department
More informationBEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS
BEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS Neil R Poulter ICCH, Imperial College London BHIVA: October 10th, 2008 Background CVD is the biggest single killer in the world CVD rates are increasing High
More informationLow-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies
Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS: WHERE DO WE STAND WITH THE NEW PRACTICE GUIDELINES? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant financial relationships
More informationHighlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM
Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM OSHP 2014 Annual Meeting Oklahoma City, OK April 4, 2014 1 Objectives
More information2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.
2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension Writing Group: Background Hypertension worldwide causes 7.1 million premature
More informationFive chapters 1. What is CVD prevention 2. Why is CVD prevention needed 3. Who needs CVD prevention 4. How is CVD prevention applied 5. Where should CVD prevention be offered Shorter, more adapted to clinical
More informationKey Issues in Cardiovascular Medicine Lindsay Saleski, DO
Key Issues in Cardiovascular Medicine Lindsay Saleski, DO Key Issues in Cardiovascular Health L i n d s a y S a l e s k i D O, M B A F a m i l y M e d i c i n e / E m e r g e n c y M e d i c i n e M i
More informationΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationsurtout qui n est PAS à risque?
3*25 min et surtout qui n est PAS à risque? 2018 ESC/ESH Hypertension Guidelines 2018 ESC-ESH Guidelines for the Management of Arterial Hypertension 28 th ESH Meeting on Hypertension and Cardiovascular
More informationDr Chris Ellis. Consultant Cardiologist Auckland
Dr Chris Ellis Consultant Cardiologist Auckland CVD Risk Prevention in NZ 2013 & Beyond: The Clinicians View Dr Chris Ellis Cardiologist Green Lane CVS Service, Cardiology Department, Auckland City Hospital
More informationDYSLIPIDEMIA TREATMENT: HYBRIDIZING CLINICAL PRACTICE GUIDELINES
DYSLIPIDEMIA TREATMENT: HYBRIDIZING CLINICAL PRACTICE GUIDELINES SATURDAY/4:30-5:30PM ACPE UAN: 0107-9999-17-249-L01-P 0.1 CEU/1.0 hr Activity Type: Knowledge-Based Learning Objectives for Pharmacists:
More informationUpdate on Cholesterol Management: The 2013 ACC/AHA Guidelines
Update on Cholesterol Management: The 2013 ACC/AHA Guidelines Ola Akinboboye MD MPH MBA Medical Director, Queens Heart institute Rosedale. Associate Professor of Clinical Medicine, Weill Medical College
More informationUpdate on Current Trends in Hypertension Management
Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student
More informationPreventing Cardiovascular Disease Stroke Primary Prevention Guidelines. John Potter Professor Ageing & Stroke Medicine University of East Anglia
Preventing Cardiovascular Disease Stroke Primary Prevention Guidelines John Potter Professor Ageing & Stroke Medicine University of East Anglia Preventing Cardiovascular Disease Stroke Primary Prevention
More informationAssessing atherosclerotic risk for long term preventive treatment
Assessing atherosclerotic risk for long term preventive treatment Donald A. Smith, MD, MPH Endocrinologist, Clinical Lipidologist Associate Professor of Medicine and Preventive Medicine Icahn School of
More informationLipoprotein Particle Profile
Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular
More informationDiabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationMEDICAL POLICY SUBJECT: CORONARY CALCIUM SCORING
MEDICAL POLICY PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More information